USOR 22118 - Ph3 Soto/Doublet vs Pembro/Doublet NSCLC PD-L1 neg KRAS PG12C+ (CodeBreaK 202)

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (20190341)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles